Compare Amgen, Inc. (AMGN) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Cenovus Energy Inc — how do they compare? Amgen, Inc. trades at $360.87 (market cap $196.12B), while Cenovus Energy Inc trades at $27.06 (market cap $49.07B). The key difference: Amgen, Inc. is far larger — about 4× Cenovus Energy Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CVE | |
|---|---|---|
Market Cap | $196.12B | $49.07B |
Sector | Health | Energy |
52-Week High | $388.16 | $31.80 |
52-Week Low | $271.18 | $13.96 |
Enterprise Value | $241.41B | $56.95B |
Dividend Yield | 2.77% | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Cenovus Energy (CVE) trades at $26.40, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.93 and net income margin of 8.94%, supported by three consecutive quarterly earnings beats. Recent news highlights its 85% annual rally, driven by oil price gains and operational synergies from MEG Energy.
The outlook remains positive given its low-cost assets and integrated model, though risks include oil price volatility and execution of growth plans. Analyst consensus is mixed with 40.7% buy ratings, reflecting cautious optimism amid energy sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
